Page last updated: 2024-12-11

1-azabicyclo(2.2.2)oct-3-yl 2-hydroxy-2-(1-iodo-1-propen-3-yl)-2-phenylacetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

The compound you described, **1-azabicyclo(2.2.2)oct-3-yl 2-hydroxy-2-(1-iodo-1-propen-3-yl)-2-phenylacetate**, is a complex organic molecule with a unique structure. While it doesn't have a common name or widely recognized importance in scientific research, it's possible it might be relevant in niche areas, such as:

**1. Potential as a Drug Lead:**

* The molecule contains a bicyclic amine (1-azabicyclo(2.2.2)octane) that is commonly found in pharmaceuticals.
* The 2-hydroxy-2-(1-iodo-1-propen-3-yl)-2-phenylacetate side chain could be modified to create pharmacologically active molecules.
* The presence of iodine could make it suitable for radiolabeling, useful in imaging studies.

**2. Synthesis and Chemical Studies:**

* The molecule's complex structure could make it a valuable starting point for developing new synthetic methods.
* Its synthesis could involve interesting reactions and provide insights into organic chemistry principles.
* The presence of the iodine atom offers opportunities for studying chemical transformations and reactivity.

**3. Potential as a Probe:**

* Due to its structure, it could be used as a probe for studying biological systems.
* The iodine atom could be exploited to study its interactions with proteins or other molecules.
* It could potentially act as a fluorescent probe or a substrate for enzymatic reactions.

**Important Note:**

* Without further information, it's impossible to pinpoint the exact importance of this molecule.
* Its relevance might be specific to a particular research group or project.
* To understand the significance of this compound, additional context is required, such as the purpose of its synthesis or its potential applications.

Therefore, while 1-azabicyclo(2.2.2)oct-3-yl 2-hydroxy-2-(1-iodo-1-propen-3-yl)-2-phenylacetate itself might not be a well-known molecule, its unique structure and potential applications make it an intriguing subject for further research.

1-azabicyclo(2.2.2)oct-3-yl 2-hydroxy-2-(1-iodo-1-propen-3-yl)-2-phenylacetate: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6438797
MeSH IDM0215146

Synonyms (7)

Synonym
iqnp
1-azabicyclo[2.2.2]octan-3-yl (e)-2-hydroxy-5-iodo-2-phenylpent-4-enoate
3-quinuclidinyl alpha-hydroxy-alpha-(1-iodo-1-propen-3-yl)-alpha-phenylacetate
1-azabicyclo(2.2.2)oct-3-yl alpha-hydroxy-alpha-(1-iodo-1-propen-3-yl)-alpha-phenylacetate
147612-55-3
benzeneacetic acid, alpha-hydroxy-alpha-(3-iodo-2-propenyl)-, 1-azabicyclo(2.2.2)oct-3-yl ester
1-azabicyclo(2.2.2)oct-3-yl 2-hydroxy-2-(1-iodo-1-propen-3-yl)-2-phenylacetate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (75.00)18.2507
2000's3 (25.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.59 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]